Autophagy Fokus PAQ Therapeutics specializes in autophagy-based degradation therapies (ATTEC) with potential to target a wide range of substrates, indicating several high-interest collaboration and licensing opportunities for partners seeking novel degradation modalities.

Strategic Alliances Active collaborations with Insilico Medicine and notable funding rounds signal a strong interest from external partners and AI-driven drug discovery ecosystems, suggesting partnership and co-development sales avenues with AI/biotech firms.

Series Growth Recent Series A and Series B financings totaling over 100 million imply a growing capital runway and appetite for further partnerships, licensing deals, and consultant or CRO collaborations to advance pipelines.

Pipeline Focus Public emphasis on KRAS ATTEC degraders and autophagy-dependent therapies points to near-term opportunities in oncology and rare disease spaces where degrader modalities may complement or substitute traditional programs.

Operational Scale Small-to-mid sized team (11-50 employees) with cloud-based tech stack and Shopify presence suggests readiness for scalable collaboration models, pilot projects, and fast onboarding for joint development initiatives.